Global biotechnology company
focusing on developing new treatments
Sub Medpacto
Sub Medpacto
The national No.1 gene analysis company, to develop innovative biomarker-based therapeutics
MedPacto is an innovative drug discovery and development company based in South Korea that develops therapeutics targeting cancer and autoimmune diseases. Our expertise lies in utilizing genome-based methods to identify novel targets and function identification through pre-clinical studies and global clinical development.
There is urgent need for new treatments that can overcome the limitations of existing anticancer drugs and MedPacto develops pipelines according to the trends’ needs.
-
Founder
Seong Jin Kim
-
Date of establishment
19 Jun. 2013
-
Head Quarter
92 Myeongdal-ro, Borim Building, Seocho-gu, Seoul 06668, Republic of Korea
‘Medical treatment, Cure, Remedy'
French
‘Agreement, Promise, Covenant’
Latin
ESG
To contribute to the lives of patients and families by developing innovative and personalized therapies that target cancer and autoimmune diseases.
We continue to invest in R&D to develop innovative new drugs discovered through basic research, and we are promoting differentiated R&D through partnerships with leading research institutes at home and abroad.
In addition, we continue to make efforts to reduce energy use and greenhouse gas emissions in advance to cope with climate change. Moreover, as a listed company that must meet social expectations, Medpacto is practicing sustainability management to satisfy all stakeholders, including employees, customers, and shareholders.
MedPacto’s Corporate Culture
To discover and develop personalized therapies to meet the needs of patients by upholding ethical standards and scientific excellence.
-
Competitive basic research
-
‘Biomarker-based’
development of innovative drugs -
Transparent and sincere company
that puts customer trust first -
Company whose
employees are proud of -
‘One MedPacto’ mind
History
MedPacto : Our Roots